Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma - PubMed (original) (raw)
Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma
S F Shariat et al. Cancer. 2001.
Abstract
Background: Elevated local and circulating levels of transforming growth factor (TGF)-beta(1) have been associated with cancer invasion, progression, and metastasis. The authors tested the hypothesis that preoperative plasma TGF-beta(1) levels would independently predict cancer stage and prognosis in patients with transitional cell carcinoma (TCC) of the urinary bladder.
Methods: The study group consisted of 51 patients who underwent radical cystectomy for muscle-invasive or intravesical immuno- and/or chemotherapy refractory Tis, Ta, or T1 TCC (median follow-up, 45.7 months). Preoperative plasma levels of TGF-beta(1) were measured and correlated with pathologic features and clinical outcome. Transforming growth factor-beta(1) levels also were measured in 44 healthy men without any cancer.
Results: The mean preoperative plasma TGF-beta(1) level in patients who eventually developed metastases to distant (11.9 +/- 0.9 ng/mL) or regional (9.6 +/- 2.4 ng/mL) lymph nodes was significantly higher than that in patients with nonmetastatic muscle-invasive TCC (5.4 +/- 1.1 ng/mL), which, in turn, was significantly higher than that in patients with nonmetastatic Tis, Ta, or T1 TCC (4.5 +/- 1.2 ng/mL) and healthy subjects (4.5 +/- 1.2 ng/mL; P < 0.001). Preoperative plasma TGF-beta(1) level was an independent predictor of lymphovascular invasion (P = 0.002), metastases to lymph nodes (P = 0.030), disease recurrence (P = 0.009), and disease specific survival (P = 0.015). In a subgroup of patients with muscle-invasive TCC, TGF-beta(1) level was associated with disease recurrence (P = 0.005) and death from bladder carcinoma (P = 0.001).
Conclusions: The authors confirm that plasma TGF-beta(1) levels are elevated in patients with muscle-invasive TCC before cystectomy. Transforming growth factor-beta(1) levels are highest in patients with bladder carcinoma metastatic to lymph nodes and are a strong independent predictor of disease recurrence and disease specific mortality.
Copyright 2001 American Cancer Society.
Similar articles
- Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy.
Shariat SF, Shalev M, Menesses-Diaz A, Kim IY, Kattan MW, Wheeler TM, Slawin KM. Shariat SF, et al. J Clin Oncol. 2001 Jun 1;19(11):2856-64. doi: 10.1200/JCO.2001.19.11.2856. J Clin Oncol. 2001. PMID: 11387358 - Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy.
Matsumoto K, Shariat SF, Casella R, Wheeler TM, Slawin KM, Lerner SP. Matsumoto K, et al. J Urol. 2003 Dec;170(6 Pt 1):2248-52. doi: 10.1097/01.ju.0000094189.93805.17. J Urol. 2003. PMID: 14634390 - Local recurrence after radical cystectomy for invasive bladder cancer: an analysis of predictive factors.
Honma I, Masumori N, Sato E, Takayanagi A, Takahashi A, Itoh N, Tamagawa M, Sato MA, Tsukamoto T. Honma I, et al. Urology. 2004 Oct;64(4):744-8. doi: 10.1016/j.urology.2004.05.003. Urology. 2004. PMID: 15491713 Review. - Management of high-risk non-muscle invasive bladder cancer.
Brausi M, Olaru V. Brausi M, et al. Minerva Urol Nefrol. 2012 Dec;64(4):255-60. Minerva Urol Nefrol. 2012. PMID: 23288212 Review.
Cited by
- Exploiting Canonical TGFβ Signaling in Cancer Treatment.
Liu Q, Chen G, Moore J, Guix I, Placantonakis D, Barcellos-Hoff MH. Liu Q, et al. Mol Cancer Ther. 2022 Jan;21(1):16-24. doi: 10.1158/1535-7163.MCT-20-0891. Epub 2021 Oct 20. Mol Cancer Ther. 2022. PMID: 34670783 Free PMC article. Review. - Molecular markers in bladder cancer.
Soria F, Krabbe LM, Todenhöfer T, Dobruch J, Mitra AP, Inman BA, Gust KM, Lotan Y, Shariat SF. Soria F, et al. World J Urol. 2019 Jan;37(1):31-40. doi: 10.1007/s00345-018-2503-4. Epub 2018 Sep 26. World J Urol. 2019. PMID: 30259123 Free PMC article. Review. - The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.
van Dijk N, Funt SA, Blank CU, Powles T, Rosenberg JE, van der Heijden MS. van Dijk N, et al. Eur Urol. 2019 Mar;75(3):435-444. doi: 10.1016/j.eururo.2018.09.022. Epub 2018 Sep 28. Eur Urol. 2019. PMID: 30274701 Free PMC article. Review. - EIF5A2 predicts outcome in localised invasive bladder cancer and promotes bladder cancer cell aggressiveness in vitro and in vivo.
Wei JH, Cao JZ, Zhang D, Liao B, Zhong WM, Lu J, Zhao HW, Zhang JX, Tong ZT, Fan S, Liang CZ, Liao YB, Pang J, Wu RH, Fang Y, Chen ZH, Li B, Xie D, Chen W, Luo JH. Wei JH, et al. Br J Cancer. 2014 Apr 2;110(7):1767-77. doi: 10.1038/bjc.2014.52. Epub 2014 Feb 6. Br J Cancer. 2014. PMID: 24504366 Free PMC article. - Revisiting Immunotherapy: A Focus on Prostate Cancer.
Cha HR, Lee JH, Ponnazhagan S. Cha HR, et al. Cancer Res. 2020 Apr 15;80(8):1615-1623. doi: 10.1158/0008-5472.CAN-19-2948. Epub 2020 Feb 17. Cancer Res. 2020. PMID: 32066566 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical